Medpace Holdings, Inc. will release its second quarter 2026 financial results after the market close on Wednesday, July 22, 2026. The company will host a conference call the following morning, Thursday, July 23, 2026, at 9:00 a.m. ET to discuss these results. A supplemental slide presentation will be available on the "Investors" section of Medpace's website prior to the start of the call.

Conference Call Details

Interested parties must register in advance to participate in the conference call. Registration is required to receive the dial-in number and a unique PIN. Participants are recommended to join 10 minutes prior to the event start time.

Access and Replay

The conference call will be accessible via webcast at investor.medpace.com. A replay of the webcast will be available at the same site approximately one hour after the call concludes. Telephone participants will receive a confirmation email with detailed instructions upon registration.

Company Overview

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO). It provides Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,300 people across 46 countries as of March 31, 2026.

Bronstein, Gewirtz & Grossman, LLC reminds investors who purchased or acquired Medpace Holdings, Inc. securities between April 22, 2025, and February 9, 2026, of the June 8, 2026 deadline to move for lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that defendants made false or misleading statements regarding the company's backlog cancellation rate and book-to-bill ratio, overstating the stability of its business and funding environment. Investors may seek compensation without out-of-pocket fees through a contingency fee arrangement.

The complaint contends that Medpace repeatedly portrayed an overly optimistic book-to-bill ratio of approximately 1.15 during earnings calls and other public communications, despite contrary internal information. These statements allegedly provided investors with overly positive growth expectations. On February 9, 2026, Medpace announced its fourth quarter 2025 book-to-bill ratio of 1.04, falling short of guidance. Following this announcement, the price of Medpace's common stock declined significantly.

Key Dates and Metrics

A class action lawsuit has already been filed. The court-appointed lead plaintiff is typically the investor with the largest financial interest in the relief sought by the class. Investors may choose to serve as lead plaintiff through counsel of their choice, select other counsel, or remain an absent class member. The decision to serve as lead plaintiff does not affect an investor's ability to share in any potential recovery. Until a class is certified, investors are not represented by counsel unless they retain one.